2. UroToday Home
  3. Conference Highlights
  4. 10th International Symposium on Targeted Alpha Therapy, TAT-10

TAT-10: Radium-223 in Asymptomatic Metastatic Castration Resistance Prostate Cancer Patients Treated in an International Early Access Program (iEAP)

Kanazawa, Japan (UroToday.com) The purpose of this study was to see if there were significant differences in asymptomatic patients at baseline compared to symptomatic patients for early treatment with Ra223. Asymptomatic was defined as no pain and no opioid use. In other selection criteria, malignant lymphadenopathy > 6cm and visceral disease were excluded.

708 patients received at least one Ra223 injection and 683 (548 symptomatic, 135 asymptomatic) received enough treatment to be evaluated. Asymptomatic patients received fewer prior treatments of abiraterone (25% vs 35%), enzalutamide (4% vs 8%), and docetaxel (52% vs 62%). Asmptomatic patients were more likely to complete the full treatment of 6 cycles of Ra223 (71% vs 55%). In addition, adverse events were less common in asymptomatic patients.

Overall survival was longer in asymptomatic patients (median 20.5 months vs 13.5 months for symptomatic). Asymptomatic patients were more likely to show alkaline phosphatase (ALP) normalization (59% vs 34%).

Presented By: Joe M. O’Sullivan from The Center for Cancer Research and Cell Biology, Queen’s University, Belfast, and the Northern Ireland Cancer Center, Belfast, Northern Ireland

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.